Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NRX PharmaceuticalsFRA:B1Q +5.42%33 PS Ratio is 56.57 as of Jul. 23, 2026, which is 14% above its 10-year median of 49.62. GuruFocus rates FRA:B1Q with a GF Score™ of 33/100. The stock has 4 warning signs investors should review. Among 930 Biotechnology companies, NRX Pharmaceuticals ranks worse than 79.89% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, NRX Pharmaceuticals's share price is €3.79.
NRX Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.07. Hence, NRX Pharmaceuticals's PS Ratio for today is 56.57.
The historical rank and industry rank for NRX Pharmaceuticals's PS Ratio or its related term are showing as below:
FRA:B1Q'
s PS Ratio Range Over the Past 10 Years
Min: 28.21 Med: 49.62 Max: 297.27
Current: 57.44
During the past 6 years, NRX Pharmaceuticals's highest PS Ratio was 297.27. The lowest was 28.21. And the median was 49.62.
FRA:B1Q's PS Ratio is ranked worse than 79.89% of 930
companies
in the Biotechnology industry
Industry Median: 9.22
vs FRA:B1Q: 57.44
NRX Pharmaceuticals (FRA:B1Q) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
NRX Pharmaceuticals PS Ratio Related Terms
NRX Pharmaceuticals PS Ratio Historical Data
* Premium members only.
The historical data trend for NRX Pharmaceuticals's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NRX Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NRX Pharmaceuticals PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where NRX Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
NRX Pharmaceuticals's Share Price of today is €3.79. NRX Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.07.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
NRX Pharmaceuticals (FRA:B1Q) has a PS Ratio of 56.57 as of Jul. 23, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on NRX Pharmaceuticals and its competitors. This is 14% above median its historical median of 49.62. Over the past decade, NRX Pharmaceuticals' PS Ratio has ranged from 28.21 to 297.27. According to the industry distribution chart, NRX Pharmaceuticals ranks #743 out of 930 companies in the Biotechnology industry, placing it in the top 79.9%.
Is NRX Pharmaceuticals' PS Ratio too high?
NRX Pharmaceuticals' current PS Ratio of 56.57 is 14% above median its 10-year median of 49.62. Over the past 10 years, this metric has ranged from a low of 28.21 to a high of 297.27. The Biotechnology industry median PS Ratio is 9.22. NRX Pharmaceuticals' value of 56.57 is 513.6% above this industry median. Based on the distribution chart, NRX Pharmaceuticals ranks #743 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NRX Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does NRX Pharmaceuticals' PS Ratio compare to CRBP and PRQR?
According to the Biotechnology industry distribution chart, NRX Pharmaceuticals ranks #743 out of 930 companies for PS Ratio. This places NRX Pharmaceuticals in the lower half of its industry. The industry median PS Ratio is 9.22. NRX Pharmaceuticals' value of 56.57 is 513.6% above this benchmark. Historically, NRX Pharmaceuticals' own PS Ratio has ranged from 28.21 to 297.27 over the past decade. While the company's 10-year median is 49.62 vs. the industry median of 9.22, NRX Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.22, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NRX Pharmaceuticals's current PS Ratio of 56.57 is 513.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on NRX Pharmaceuticals and its competitors. For the Biotechnology industry, the median PS Ratio is 9.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NRX Pharmaceuticals's current PS Ratio is 56.57, which is 14% above median its own 10-year median of 49.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NRX Pharmaceuticals stock overvalued right now?
NRX Pharmaceuticals (FRA:B1Q) has a current PS Ratio of 56.57. The current PS Ratio is 56.57, which is 14% above median its 10-year median of 49.62 and 513.6% above the Biotechnology industry median of 9.22. NRX Pharmaceuticals' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For NRX Pharmaceuticals (FRA:B1Q), the current PS Ratio is 56.57 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
33GF Score
Get the complete analysis for FRA:B1Q
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:B1Q has been successfully added to your 
